NRC Stock Overview
A commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Neuronetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.56 |
| Beta | 2.22 |
| 11 Month Change | 1.88% |
| 3 Month Change | -1.81% |
| 1 Year Change | -35.37% |
| 33 Year Change | -77.40% |
| 5 Year Change | -79.57% |
| Change since IPO | -94.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 35.7% | 2.4% | 0.8% |
| 1Y | -35.4% | -5.0% | 9.1% |
Return vs Industry: NRC underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: NRC underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| NRC volatility | |
|---|---|
| NRC Average Weekly Movement | 19.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NRC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NRC's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 201 | Keith Sullivan | neurostar.com |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Neuronetics, Inc. Fundamentals Summary
| NRC fundamental statistics | |
|---|---|
| Market cap | €25.59m |
| Earnings (TTM) | -€34.70m |
| Revenue (TTM) | €69.28m |
0.4x
P/S Ratio-0.8x
P/E RatioIs NRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRC income statement (TTM) | |
|---|---|
| Revenue | US$72.71m |
| Cost of Revenue | US$15.77m |
| Gross Profit | US$56.94m |
| Other Expenses | US$93.36m |
| Earnings | -US$36.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 78.31% |
| Net Profit Margin | -50.09% |
| Debt/Equity Ratio | 490.4% |
How did NRC perform over the long term?
See historical performance and comparison